Tofacitinib: A Promising Treatment for Adolescent Alopecia Areata

The document presents a case study of a 14-year-old male patient with severe and refractory alopecia areata (AA), an autoimmune skin disorder causing hair loss, treated with tofacitinib, a Janus kinase (JAK) inhibitor. Previous treatments had yielded suboptimal results. Tofacitinib therapy was initiated at a dose of 5 mg twice daily, leading to complete hair regrowth within 2 months. The dose was then tapered to 5 mg once daily and supplemented with topical therapies. After 5 months, the patient's condition improved significantly, allowing for the discontinuation of tofacitinib. The patient maintained hair growth using topical therapies for a 10-month observation period. No serious adverse events associated with tofacitinib use were observed. The case highlights the potential of tofacitinib as an effective and well-tolerated treatment for AA in adolescents, particularly in the Indian population, and emphasizes the need for further research.